Alnylam highlights new data from helios-b study of vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy at heart failure society of america annual scientific meeting 2024

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that two new data sets from the helios-b phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of attr amyloidosis with cardiomyopathy (attr-cm), were presented in the late breaking clinical research session 1 at the heart failure society of america (hfsa) annual scientific meeting 2024, which was held virtually. an o.
ALNY Ratings Summary
ALNY Quant Ranking